Table 3.
Accuracy of an edoxaban-calibrated anti-Xa assay for measuring all anti-Xa inhibitors: apixaban, rivaroxaban, and edoxaban. Patients treated in clinical practice were enrolled in a multicenter cross-sectional study (n = 553). An LC-MS/MS analysis was performed as a reference standard.
| Rivaroxaban | Apixaban | Edoxaban | All | |
|---|---|---|---|---|
| Spearman’s correlation coefficient (95% CI) | 0.95 (0.94, 0.96) |
0.93 (0.91, 0.95) |
0.93 (0.86, 0.97) |
0.94 (0.93, 0.95) |
|
Deming regression slope (95% CI) |
0.78 (0.70, 0.87) |
1.01 (0.94, 1.08) |
0.90 (0.83, 0.96) |
0.86 (0.79, 0.92) |
| Y-Intercept | 14.08 (6.28, 21.87) |
−11.39 (−19.25, −3.53) |
21.73 (10.69, 32.77) |
6.97 (0.74, 13.19) |